In lupus patients presenting with demyelinating symptoms, consider a probable disease overlap between NPSLE and NMOSD. >>>> serum AQP4 is highly specific for NMOSD. @RheumNow #APLAR25 @rheumarhyme @marklagacmd https://t.co/2Z8rbJ3a1c

Different B cells depletion strategies in SARDs highlighted by Georg Schett From low and short lived depletion achieved w/ drugs to sustained deep tissular depletion with CAR T cells leading to potential immune reset @RheumNow #APLAR25 https://t.co/t35lrzEomF

Juvenile Lupus: some new mechanistic data Circulating Treg population are expanded in SLE and in particular in Lupus Nephritis compared to HC Naive Treg display specific molecular features in particular over expression of FCRL3 and TLR5 showing new pathways to explore in https://t.co/RuMtWRkpYB

PAH, when associated with ILD in CTD, worsens prognosis, and poses challenges for treatment Summary of when PAH should be assessed in patients with ILD and when to perform a right heart catheterization by Prof Kuwana @RheumNow #APLAR25 https://t.co/g4x4ENzc9k

Dr. Alberta Hoi graphically presents the difference bet acute confusional states & chronic cognitive changes in #lupus patients presenting with NP symptoms. NPSLE continues to pose a diagnostic challenge bec pts may present with more than one syndrome complex @RheumNow #APLAR25 https://t.co/4nYTo1fzVz

How to treat CTD ILD? A comparative slide summarizing ACR/BSR and EULAR treatment guidelines Emphasis on combination of Immunosuppressant and Antifibrotics @RheumNow #APLAR25 https://t.co/gLSht6QKh5

A framework for treatment stratified approach in CTD-ILD, by Dr Low Hsiu Ling Based on -ILD extent -Risk of progression -Biology: fibrosis/inflammation -Safety -Other manifestations @RheumNow #APLAR25 https://t.co/ma5KugzBHy

‼️More reasons why we should avoid steroids in #lupus patients @RheumNow #APLAR25 https://t.co/a5IeutJ5mi

Why shall we screen all patients with SSc for ILD? Focusing screening strategy on patients « at risk » misses 25% of patients with ILD ILD being the main cause of mortality in SSc @RheumNow #APLAR25 https://t.co/djzCTdZoVb

The overall prevalence of #osteoporosis in SLE is ~33-40% and is due to several factors with GC therapy being one of them. Monitor DXA every 6-12 months (vs. 2 yrs for standard OP) ☝️Screen for GIOP ☝️Treat accordingly - once on GCs & esp w/long-term use @RheumNow #APLAR25 https://t.co/E9FJDHrBUo

Paradigm shift in CTD PAH -Early triple therapy in patients with intermediate and high risk -Sotatercept, a blocker of activin-Smad2/3 signaling have increased survival importantly Data presented by Dr Khanna @RheumNow #APLAR25 https://t.co/Z4yA6DwtOb